Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04951778 | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With… | Phase 1 | terminated | Jul 7, 2021 | Celgene | Efficacy endpoint met; however, overall experimental dosing regimen is not considered optimal to… | Efficacy / futility |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | Phase 2 | terminated | Dec 7, 2018 | Technische Universität Dresden | Feasibility | Other (stated, no rule matched) |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With… | Phase 1 / Phase 2 | terminated | Nov 7, 2024 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT00015847 | Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous… | Phase 2 | terminated | Jan 27, 2003 | OHSU Knight Cancer Institute | not stated | Not stated |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in… | Phase 1 / Phase 2 | terminated | Jul 18, 2024 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed… | Phase 1 / Phase 2 | terminated | Sep 2, 2021 | M.D. Anderson Cancer Center | The study was terminated early due to slow enrollment. | Enrollment / accrual |
| NCT05655546 | ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised… | N/A | terminated | Dec 19, 2022 | Scripps Translational Science Institute | On May 13, 2024, the FDA released a communication that Cue Health tests should no longer be used. | Other (stated, no rule matched) |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic…(B-ALL) | Phase 1 / Phase 2 | withdrawn | Aug 24, 2023 | Juventas Cell Therapy Ltd. | Sponsor changed product development plan | Other (stated, no rule matched) |
| NCT06474663 | A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and… | Phase 1 | withdrawn | Jun 26, 2024 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT04849910 | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein,… | Phase 1 / Phase 2 | terminated | Apr 19, 2021 | Vor Biopharma | Lack of Funding | Funding |
| NCT05309733 | A Long-term Follow-up Study of Patients Who Received VOR33 | — | terminated | Apr 4, 2022 | Vor Biopharma | Lack of Funding | Funding |
| NCT05984199 | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Aug 9, 2023 | Vor Biopharma | Lack of Funding | Funding |
| NCT05817058 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute… | Phase 1 | terminated | Apr 18, 2023 | Affimed GmbH | As decided by sponsor | Other (stated, no rule matched) |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | — | terminated | Oct 14, 2019 | AstraZeneca | Study stopped due to lack of recruitment. | Enrollment / accrual |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT05209152 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic… | Phase 1 | terminated | Jan 26, 2022 | Amgen | Sponsor decision, unrelated to safety | Safety / toxicity |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | N/A | withdrawn | Aug 1, 2023 | Neena Kapoor, M.D. | No funding available. | Funding |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2021 | Kite, A Gilead Company | Study was terminated due to futility | Efficacy / futility |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT06013904 | Difficult PIV Placement in the Pediatric ED | N/A | withdrawn | Aug 28, 2023 | University of Texas at Austin | The logistics of the study made it too challenging to conduct within a pediatric setting. | Other (stated, no rule matched) |
| NCT01688011 | Connect® Myeloid Disease Registry | — | terminated | Sep 19, 2012 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT07046481 | Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up | N/A | withdrawn | Jul 1, 2025 | Region Skane | Registration was withdrawn from clinicaltrials.gov as the ISRCTN registry was found to be more… | Other (stated, no rule matched) |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Phase 1 | terminated | Jul 5, 2022 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and… | Phase 1 | withdrawn | Aug 30, 2022 | Janssen Research & Development, LLC | Business Decision | Sponsor / business decision |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute… | Phase 1 / Phase 2 | terminated | Oct 30, 2018 | National Cancer Institute (NCI) | Other - Study agent no longer available | Other (stated, no rule matched) |
| NCT02848001 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Jul 28, 2016 | Celgene | Trial terminated because of lack of efficacy in the short term acute phase. | Efficacy / futility |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute… | Phase 1 | withdrawn | Feb 21, 2022 | Beijing Boren Hospital | no patients | Other (stated, no rule matched) |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With…(AMpLify) | Phase 1 | terminated | Nov 13, 2023 | Caribou Biosciences, Inc. | Sponsor Decision - Pipeline Reprioritization | Sponsor / business decision |
| NCT01251965 | Phase l/II Study of Ruxolitinib for Acute Leukemia | Phase 1 / Phase 2 | terminated | Dec 2, 2010 | M.D. Anderson Cancer Center | Study was stopped by the principal investigator due to nonsatisfactory clinical benefit even in… | Investigator |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Study was closed early due to low accrual and lack of response. | Enrollment / accrual |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT01751425 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual… | Phase 1 | terminated | Dec 18, 2012 | M.D. Anderson Cancer Center | Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib. | Other (stated, no rule matched) |
| NCT05292898 | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With… | Phase 1 | terminated | Mar 23, 2022 | Institute of Hematology & Blood Diseases Hospital, China | Achieve the proof of concept | Other (stated, no rule matched) |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic…(CORONADO CLL) | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | University of Utah | This study was terminated due to sponsor de-activation of all programs associated with RP-3500… | Other (stated, no rule matched) |
| NCT06770257 | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML… | Phase 2 | withdrawn | Jan 13, 2025 | Institute of Hematology & Blood Diseases Hospital, China | The project was terminated as the genetic office did not approve it. | Other (stated, no rule matched) |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | Phase 1 / Phase 2 | terminated | May 9, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Poor accrual | Enrollment / accrual |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT04789655 | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not… | Phase 1 / Phase 2 | terminated | Jun 10, 2024 | Institute of Hematology & Blood Diseases Hospital, China | The number of participants in the study did not meet expectations | Other (stated, no rule matched) |
| NCT06572631 | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for… | Phase 1 | withdrawn | Aug 27, 2024 | City of Hope Medical Center | cprmc withdrawn | Other (stated, no rule matched) |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | Phase 2 | withdrawn | Dec 28, 2020 | Inhye Ahn | Bayer is no longer funding due to lack of accrual | Enrollment / accrual |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute… | Phase 1 / Phase 2 | terminated | May 25, 2018 | Sumithira Vasu | Poor acccrual | Other (stated, no rule matched) |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Phase 1 | terminated | Jan 17, 2018 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute… | Phase 1 / Phase 2 | terminated | Jul 7, 2022 | Novartis Pharmaceuticals | Study has been stopped following the strategic decision from the Sponsor. Not based on any safety… | Safety / toxicity |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | Phase 2 | terminated | Sep 21, 2020 | Michael Burke | poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 27, 2025source: clinicaltrials